NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
9.46
+0.03 (0.32%)
At close: Mar 6, 2026, 4:00 PM EST
9.37
-0.09 (-0.95%)
After-hours: Mar 6, 2026, 4:10 PM EST
NTHI Revenue
NeOnc Technologies Holdings had revenue of $59.99K in the twelve months ending September 30, 2025, down -4.78% year-over-year. In the year 2024, NeOnc Technologies Holdings had annual revenue of $83.00K with 17.79% growth.
Revenue (ttm)
$59.99K
Revenue Growth
-4.78%
P/S Ratio
3,134.48
Revenue / Employee
n/a
Employees
n/a
Market Cap
188.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
| Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
| Dec 31, 2022 | 20.00K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNTHI News
- 2 days ago - NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET - GlobeNewsWire
- 7 days ago - NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity - GlobeNewsWire
- 5 weeks ago - NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management - GlobeNewsWire
- 2 months ago - Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) - Newsfile Corp
- 2 months ago - NeOnc Technologies Reports Updated Clinical Results - GlobeNewsWire
- 3 months ago - NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors - GlobeNewsWire
- 4 months ago - NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) - GlobeNewsWire
- 4 months ago - NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program - GlobeNewsWire